Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.

Amelia McCartney Martina BonechiFrancesca De LucaChiara BiagioniCurigliano GiuseppeErica MorettiAlessandro Marco MinisiniMattias BergqvistMatteo BenelliIlenia MigliaccioFrancesca GalardiEmanuela RisiIrene De Santo Dario RomagnoliLaura BiganzoliAngelo Di LeoLuca Malorni

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

TK is a dynamic marker of resistance to palbociclib which may lead to early identification of patients in whom treatment escalation may be feasible. In addition, TKa may stratify prognosis in patients with acquired resistance to palbociclib.

Keyphrases

metastatic breast cancer
newly diagnosed
end stage renal disease
ejection fraction
prognostic factors
study protocol
randomized controlled trial
open label
phase iii
patient reported outcomes
tyrosine kinase